Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease
Pavlovsky, S.; Maschio, M.; Santarelli, M.T.; Muriel, F.S.; Corrado, C.; Garcia, I.; Schwartz, L.; Montero, C.; Sanahuja, F.L.; Magnasco, O.
Journal of the National Cancer Institute 80(18): 1466-1473
1988
ISSN/ISBN: 0027-8874 PMID: 3184196 Document Number: 314570
A total of 277 patients with untreated Hodgkin's disease, clinical stages I-II, were randomized to cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) alone for 6 monthly cycles or to CVPP plus radiation therapy (RT), 3,000 rad, to involved areas (CVPP plus RT). One or more of the following factors were considered as unfavorable prognosis: age > 45 years, more than two lymph node areas involved, or bulky disease. In the favorable group, disease-free survival (77% vs. 70%) or overall survival (92% vs. 91%) at 84 months for CVPP versus RT plus CVPP was similar. Patients with unfavorable prognosis treated with RT plus CVPP had longer disease-free survival (75% vs. 34%) (P = .001) and overall survival (84% vs. 66%) than patients treated with CVPP alone.